



Pluristem CEO Zami Aberman Elected to Board of Directors of the Alliance for Regenerative Medicine

ARM is the preeminent global advocate for the advancement of regenerative medicine

HAIFA, ISRAEL, October 7, 2015 -- [Pluristem Therapeutics Inc.](#) (NasdaqCM: PSTI) (TASE: PSTI), a leading developer of placenta-based cell therapy products, today announced that its Chairman and CEO, Zami Aberman, has been elected to serve on the Board of Directors of the [Alliance for Regenerative Medicine \(ARM\)](#). Based in Washington, D.C., ARM promotes research, development, investment and commercialization of regenerative medicine technologies. Pluristem has been a member of ARM for 3 years and has actively supported the organization's goals. Mr. Aberman joins other prominent leaders in the field of regenerative medicine who are currently serving on the board.

Dr. Karine Kleinhaus, Divisional Vice President, North America, will present at 10:45 a.m. on October 7 at the Stem Cell Meeting on the Mesa to be held October 7-9, 2015 in La Jolla, California. Co-hosted by ARM, the California Institute for Regenerative Medicine (CIRM) and the Sanford Consortium for Regenerative Medicine, the 2015 Stem Cell Meeting on the Mesa is attended by leading cell therapy, gene therapy and tissue engineering companies, large pharma and biotech, industry investors and major academic research institutions. A live video webcast of the presentation will be available at: <http://stemcellmeetingonthemesa.com/webcast/> and will also be published on ARM's website shortly after the event.

About Pluristem Therapeutics

Pluristem Therapeutics Inc. is a leading developer of placenta-based cell therapy products. The Company has reported robust clinical trial data in multiple indications for its patented PLX (PLacental eXpanded) cells. The cells release a cocktail of therapeutic proteins in response to inflammation, ischemia, hematological disorders, and radiation damage. PLX cell products are grown using the Company's proprietary three-dimensional expansion technology. They are off-the-shelf, requiring no tissue matching prior to administration.

Pluristem has a strong intellectual property position; Company-owned, GMP-certified manufacturing and research facilities; strategic relationships with major research institutions; and a seasoned management team.

Contact:

Pluristem Therapeutics Inc.
Karine Kleinhaus, MD, MPH
Divisional VP, North America
1-914-512-4109
karinek@pluristem.com